Toevoeging daratumumab aan standaardbehandeling verbetert overleving bij multipel myeloom
Daratumumab is een middel dat zich richt op het eiwit CD38, vooral sterk aanwezig in myeloom cellen. Door zich te binden aan het eiwit zorgt daratumumab ervoor dat het eigen immuunsysteem wordt geactiveerd en het multipel myeloom beter kan worden bestreden. In dit onderzoek werd gekeken wat het effect is van daratumumab in combinatie met […]

Aanbevolen

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06
Thank you so much for your time, Professor Curigliano. Congratulations on your nomination as president of ESMO. That’s a big deal and it’s going t...
Oncologie
VieCuri tekent als eerste ziekenhuis van Nederland het Zonvenant voor het voorkomen van huidkanker
Nationaal Huidfonds wil krachten bundelen In het Zonvenant is afgesproken dat VieCuri minimaal 3 jaar actief bijdraagt aan het voorkomen van huidkanke...

Oncologie nieuws

Borst

Daiichi Sankyo submits Enhertu sNDA to Japan's MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer
pharmabiz.com
Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with HER2 low (IHC 1+ or IHC 2+/ISH─) or ultralow (IHC 0 with membrane staining) unresectable or recurrent breast cancer.
Trial to diagnose breast cancer more quickly
bbc.com
A scheme to let women with symptoms book an appointment directly with a clinic is being trialled.
Toon meer

Hoofd-hals

Development of a Preclinical Double Model of Mandibular Irradiated Bone and Osteoradionecrosis in New Zealand Rabbits
onlinelibrary.wiley.com
Radiotherapy (RT) plays a crucial role in head and neck (HN) cancer treatment. Nevertheless, it can lead to serious and challenging adverse events suc...
Toon meer

Immuno-oncologie

How a potent immune therapy loses its punch against a blood cancer
nature.com
Nature, Published online: 02 October 2024; doi:10.1038/d41586-024-03141-7
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma
gut.bmj.com
The determinants of the response to checkpoint immunotherapy in hepatocellular carcinoma (HCC) remain poorly understood. The organisation of the immun...
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
nature.com
Nature Medicine, Published online: 30 September 2024; doi:10.1038/s41591-024-03240-y
Toon meer

MDL

Management of Portal vein Thrombosis in Cirrhosis
dx.doi.org
Portal vein thrombosis (PVT) is one of the common complications of cirrhosis. The incidence of PVT correlates with liver disease severity—higher inc...
Toon meer

Pediatrie

[Correspondence] Adverse obstetric outcomes in female survivors of adolescent and young adult cancers
thelancet.com
The study by Ceren Sunguc and colleagues1 has revealed that, in England, female survivors of adolescent and young adult cancers have lower overall fertility rates than expected, with survivors of cervical cancer and leukaemia facing a multitude of serious obstetric complication risks during pregnancy and childbirth. These findings indicate the need for heightened attention and specialised prenatal care for these individuals. However, we believe there are several key underlying issues within the study that could affect the interpretation of the results.
Toon meer

Sarcoom

M
Malignant Melanotic Nerve Sheath Tumor
curesarcoma.org
Malignant melanotic nerve sheath tumor (MMNST) is a rare peripheral nerve sheath tumor composed uniformly of Schwann cells showing melanocytic differe...
Toon meer